Cited by 136Rheumatoid Arthritis Research and TherapiesNatural Compounds in Disease TreatmentAutoimmune and Inflammatory Disorders Research

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Leflunomide: A Review of its Use in Active Rheumatoid Arthritis

Prakash, Amitabh, Jarvis, Blair·1999·Drugs

DOI 10.2165/00003495-199958060-00010

Open this paper in CoChat — free account

Abstract

Unlabelled A77 1726, the active metabolite of leflunomide, is an immunomodulator which inhibits cell proliferation in activated lymphocytes in patients with active rheumatoid arthritis. Because A77 1726 has a long half-life (approximately 2 weeks), treatment with oral leflunomide is initiated with a loading dose of 100mg once daily for 3 days and continued with 20mg once daily. Results of large randomised, double-blind, multicentre trials of up to 24 months' duration have shown that leflunomide is significantly superior to placebo and at least as effective as sulfasalazine in improving primary outcome measures, such as tender joint counts, swollen joint counts and physicians' and patients' global assessment, in adult patients with active rheumatoid arthritis. Whereas improvement in all primary outcome measures with leflunomide was similar to or significantly less than that with methotrexate after 12 months, the efficacy of both agents was similar after 24 months. The therapeutic effect of leflunomide appears earlier (at 4 weeks) than that of sulfasalazine or methotrexate, and reduction from baseline values in functional disability was significantly greater with leflunomide than with sulfasalazine, methotrexate or placebo at end-point. Leflunomide was at least as effective as sulfasalazine or methotrexate in delaying the rate of radiological progression of disease. The most common adverse events reported in patients receiving leflunomide in randomised double-blind, placebo-controlled trials were diarrhoea (27%), respiratory infections (21%), nausea (13%), headache (13%), rash (12%), increased serum hepatic aminotransferases (10%), dyspepsia (10%) and alopecia (9%). Leflunomide was as well tolerated as sulfasalazine or methotrexate in clinical trials. Monitoring of serum hepatic enzyme levels is recommended in patients receiving leflunomide. The drug is not recommended in female patients who are or may become pregnant. Drug treatment should be discontinued, and hastened drug elimination procedure should be considered, in male patients wishing to father a child. 16 potential cases of pancytopenia and 9 cases of serious skin reactions have been associated with the use of leflunomide in 76,000 patients to date. Conclusions Leflunomide is a disease-modifying antirheumatic drug which reduces the signs and symptoms of inflammatory arthritis and delays the radiological progression of disease in adult patients with active rheumatoid arthritis. The drug appears to be as effective and as well tolerated as sulfasalazine or methotrexate, and represents a suitable alternative to these agents in adult patients with active rheumatoid arthritis. Benefits with leflunomide are evident within 4 weeks and efficacy is maintained for durations of up to 24 months.

Integrity signals

Registry

Crossref · 10.2165/00003495-199958060-00010

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,753
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Fürst, D. E., Goldsmith, C. H., Katz, L. M. G., Lightfoot, R. W., Paulus, H. E., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,825
A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,080
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial
Möttönen, T. T., Hannonen, P., Leirisalo‐Repo, M., Nissilä, M., Kautiainen, H., Korpela, M. M., Laasonen, L., Julkunen, H. A., Luukkainen, R., Vuori, K., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08513-4 · Cited by 865
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial
Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Strand, V. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2542 · Cited by 755
Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset
McQueen, F. M., Stewart, N. R., Crabbe, J. P., Robinson, E. T., Yeoman, S., Tan, P., & McLean, L. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.6.350 · Cited by 507
Mechanism of Action for Leflunomide in Rheumatoid Arthritis
Fox, R. I., Herrmann, M. L., Frangou, C. G., Wahl, G. M., Morris, R. E., Strand, V., & Kirschbaum, B. J. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4777 · Cited by 425
Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides
van der Heijden, I. M., Wilbrink, B., Tchetverikov, I., Schrijver, I. A., Schouls, L. M., Hazenberg, M. P., Breedveld, F. C., & Tak, P. P. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200003)43:3 · Cited by 375

Show all 67 references

Sorted by citations

Guidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A. B., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Voorhees, A. S. V., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 766
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 555
Biotransformation Reactions of Five-Membered Aromatic Heterocyclic Rings
Dalvie, D., Kalgutkar, A. S. S., Khojasteh-Bakht, S. C., Obach, R. S., & O’Donnell, J. P. (2002) · Chemical Research in Toxicology · doi:10.1021/tx015574b · Cited by 523
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Next generation organofluorine containing blockbuster drugs
Han, J., Remete, A. M., Dobson, L. S., Kiss, L., Izawa, K., Moriwaki, H., Soloshonok, V. A., & O’Hagan, D. (2020) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2020.109639 · Cited by 316
The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics
YASUDA, Y., KALETA, J., & Brömme, D. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.013 · Cited by 302
Clinical Pharmacokinetics of Leflunomide
Rozman, B. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00003 · Cited by 250
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Benefit-Risk Assessment of Leflunomide
Alcorn, N., Saunders, S., & Madhok, R. (2009) · Drug Safety · doi:10.2165/11316650-000000000-00000 · Cited by 157
IN VITRO METABOLISM STUDIES ON THE ISOXAZOLE RING SCISSION IN THE ANTI-INFLAMMATORY AGENT LEFLUNOMIDE TO ITS ACTIVE α-CYANOENOL METABOLITE A771726: MECHANISTIC SIMILARITIES WITH THE CYTOCHROME P450-CATALYZED DEHYDRATION OF ALDOXIMES
Kalgutkar, A. S. S., Hang, N. T. T., Vaz, A. D. N., Doan, A., Dalvie, D., McLeod, D., & Murray, J. C. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1240 · Cited by 116
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives
Sarkar, C. K., Mondal, M., Islam, M. T., Martorell, M., Docea, A. O., Maroyi, A., Sharifi‐Rad, J., & Călina, D. C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.572870 · Cited by 98
Etanercept
Culy, C. R., & Keating, G. M. (2002) · Drugs · doi:10.2165/00003495-200262170-00013 · Cited by 89
Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data.
Chambers, C., Tutuncu, Z. N., Johnson, D., & Jones, K. L. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1977 · Cited by 88
Effect of Competition Bias in Safety Signal Generation
Pariente, A., Avillach, P., Salvo, F., Thiessard, F., Miremont‐Salamé, G., Fourrier‐Réglat, A., Haramburu, F., Bégaud, B., & Moore, N. D. (2012) · Drug Safety · doi:10.1007/bf03261981 · Cited by 85
Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice
Fukushima, R., Kanamori, S., Hirashiba, M., Hishikawa, A., Muranaka, R.-I., Kaneto, M., Nakamura, K., & Kato, I. (2007) · Reproductive Toxicology · doi:10.1016/j.reprotox.2007.05.006 · Cited by 81
The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF‐κB ligand–stimulated induction of nuclear factor of activated T cells c1
Urushibara, M., Takayanagi, H., Koga, T., Kim, S., Isobe, M., Morishita, Y., Nakagawa, T., Loeffler, M. L., Kodama, T., Kurosawa, H., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20206 · Cited by 76
Structure of Dihydroorotate Dehydrogenase B
Rowland, P., Norager, S., Jensen, K. F., & Larsen, S. (2000) · Structure · doi:10.1016/s0969-2126(00)00530-x · Cited by 75
Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery
Kesharwani, D., Paliwal, R., Satapathy, T., & Paul, S. D. (2019) · Journal of pharmacopuncture · doi:10.3831/kpi.2019.22.029 · Cited by 72
Leflunomide: A Drug with a Potential Beyond Rheumatology
Teschner, S., & Burst, V. R. (2010) · Immunotherapy · doi:10.2217/imt.10.52 · Cited by 69
Leflunomide-induced acute hepatitis
Mantilla, C. S., Ortega, L. M., Agúndez, J. A. G., Fernández‐Gutiérrez, B., Ladero, J. M., & Diaz-Rubio, M. E. (2003) · Digestive and Liver Disease · doi:10.1016/j.dld.2003.06.002 · Cited by 67
An overview of metal-free synthetic routes to isoxazoles: the privileged scaffold
Das, S., & Chanda, K. (2021) · RSC Advances · doi:10.1039/d1ra04624a · Cited by 60
Folate decorated chitosan-chondroitin sulfate nanoparticles loaded hydrogel for targeting macrophages against rheumatoid arthritis
Siddiqui, B., Rehman, A. U., Gul, R., Chaudhery, I., Shah, K. U., & Ahmed, N. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121683 · Cited by 60
Calcium-mediated one-pot preparation of isoxazoles with deuterium incorporation
Ledovskaya, M. S., Rodygin, K. S., & Ananikov, V. P. (2017) · Organic Chemistry Frontiers · doi:10.1039/c7qo00705a · Cited by 56
Leflunomide-Associated Pancytopenia With or Without Methotrexate
Chan, J. H., Sanders, D. C., Du, L., & Pillans, P. I. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e012 · Cited by 56
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review
Alamri, R. D., Elmeligy, M. A., Albalawi, G. A., Alquayr, S. M. A., Alsubhi, S. S., & El-Ghaiesh, S. H. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107398 · Cited by 53
Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes
Bérard, A., Zhao, J., Shui, I. M., & Colilla, S. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212078 · Cited by 51
Active leflunomide metabolite inhibits interleukin 1β, tumour necrosis factor α, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures
Elkayam, O., Yaron, I., Shirazi, I., Judovich, R., Caspi, D., & Yaron, M. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.5.440 · Cited by 49
Leflunomide Efficacy and Pharmacodynamics for the Treatment of BK Viral Infection
Krisl, J. C., Taber, D. J., Pilch, N. A., Chavin, K. D., Bratton, C. F., Thomas, B. S., McGillicuddy, J. W., & Baliga, P. K. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12531211 · Cited by 47
Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry
Parekh, J. M., Vaghela, R. N., Sutariya, D. K., Sanyal, M., Yadav, M. S., & Shrivastav, P. S. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.06.028 · Cited by 45
Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis
Sato, T., Inokuma, S., Sagawa, A., Matsuda, T., Takemura, T., Otsuka, T., Saeki, Y., Takeuchi, T., & Sawada, T. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/kep227 · Cited by 44
Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatography
Chan, V., Charles, B. G., & Tett, S. E. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.01.016 · Cited by 44
Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial
Poór, G., & Strand, V. (2004) · Lara D. Veeken · doi:10.1093/rheumatology/keh168 · Cited by 44
Anti-HIV-1 activity of leflunomide
Schläpfer, E., Fischer, M., Ott, P., & Speck, R. F. (2003) · AIDS · doi:10.1097/00002030-200307250-00005 · Cited by 40
Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea.
Schläpfer, E., Fischer, M., Ott, P., & Speck, R. F. (2003) · PubMed · doi:10.1097/01.aids.0000072664.21517.ad · Cited by 38
Pregnancy and Renal Failure
Keller, F., Grießhammer, M., ussler, U. H., Paulus, W. E., & Schwarz, A. (2001) · Drugs · doi:10.2165/00003495-200161130-00003 · Cited by 39
Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases
Meyer, K. C., Decker, C., & Baughman, R. P. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.05.006 · Cited by 38
Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy
Lou, T., WANG, C., Chen, Z.-J., Shi, C., TANG, H., Liu, X., YIN, P., & Yu, X. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00547.x · Cited by 34
Fatal hepatitis with leflunomide and itraconazole
Legras, A., Bergemer-Fouquet, A.-M., & Jonville‐Béra, A. ‐. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01177-4 · Cited by 34
Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents
Gan, E. Y., Chong, W., & Tey, H. L. (2013) · BioDrugs · doi:10.1007/s40259-013-0025-6 · Cited by 32
Systemic Vasculitis: Still a Challenging Disease
Buhăescu, I., Covic, A. C., & Levy, J. B. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.04.018 · Cited by 30
Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis
Garnock-Jones, K. P. (2013) · CNS Drugs · doi:10.1007/s40263-013-0118-2 · Cited by 28
Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort
Cui, X., Dai, X., Ma, L., Yang, C., Tan, W., Zhang, L., Zhang, Z., Feng, X., Wu, R., Zou, Y., et al. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.06.009 · Cited by 27
Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis
Molina, C., Modesto, C., Begué, N. M., & Arnal, C. (2013) · Clinical Rheumatology · doi:10.1007/s10067-013-2315-2 · Cited by 27
Autoimmune Rheumatic Diseases in Women
Schuna, A. A. (2002) · Journal of the American Pharmaceutical Association (1996) · doi:10.1331/108658002763029599 · Cited by 26
Leflunomide for the treatment of rheumatoid arthritis
Miceli‐Richard, C., & Dougados, M. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.987 · Cited by 27
Elucidation of a Novel Bioactivation Pathway of a 3,4-Unsubstituted Isoxazole in Human Liver Microsomes: Formation of a Glutathione Adduct of a Cyanoacrolein Derivative after Isoxazole Ring Opening
Yu, J., Folmer, J. J., Hoesch, V., Doherty, J. B., Campbell, J. B., & Burdette, D. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036285 · Cited by 25
Leflunomide in the treatment of psoriasis: results of a phase II open trial
Tlacuilo-Parra, J. A., Guevara‐Gutiérrez, E., RODRÍGUEZ-CASTELLANOS, M. A., Ornelas-Aguirre, J. M., Barba‐Gómez, J. F., & Salazar-Páramo, M. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05836.x · Cited by 25
Lipid-based nanocarriers: an attractive approach for rheumatoid arthritis management
Zewail, M. B., Doghish, A. S., El‐Husseiny, H. M., Mady, E. A., Mohammed, O. A., Elbadry, A. M. M., Elbokhomy, A. S., Bhnsawy, A., & El‐Dakroury, W. A. (2024) · Biomaterials Science · doi:10.1039/d4bm01058b · Cited by 28
Leflunomide in dermatology
Boyd, A. S. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.08.025 · Cited by 24
Photodistributed Lichenoid Drug Eruption with Rhabdomyolysis Occurring during Leflunomide Therapy
de Gutiérrez, E. M. R., & Abaca, H. (2004) · Dermatology · doi:10.1159/000077307 · Cited by 24
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany
Schädlich, P. K., Zeidler, H. K., Zink, A., Gromnica‐Ihle, E., Schneider, M., Straub, C., Brecht, J. G., & Huppertz, E. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523040-00008 · Cited by 24
Hepatoprotective effects of carvedilol and crocin against leflunomide-induced liver injury
Sokar, S. S., Alkabbani, M. A., Akool, E., & Abu-Risha, S. E.-S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109297 · Cited by 23
Competitive Copper Catalysis in the Condensation of Primary Nitro Compounds with Terminal Alkynes: Synthesis of Isoxazoles
Baglieri, A., Meschisi, L., Sarlo, F. D., & Machetti, F. (2016) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201600897 · Cited by 23
Short-Term Efficacy and Safety of???Leflunomide in the Treatment of???Active Rheumatoid Arthritis in Everyday Clinical Use
Nguyen, M., Kabir, M., & Ravaud, P. (2004) · Clinical Drug Investigation · doi:10.2165/00044011-200424020-00005 · Cited by 23
Treatment of Proliferative Lupus Nephritis—A Critical Approach
Buhăescu, I., Covic, A. C., & Deray, G. (2006) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.09.002 · Cited by 23
Leflunomide: long-term clinical experience and new uses
Kaltwasser, J. P., & Behrens, F. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.5.787 · Cited by 23
The Significance of Heterocycles for Pharmaceuticals and Agrochemicals*
Lamberth, C., & Dinges, J. (2012) · doi:10.1002/9783527664412.ch1 · Cited by 23
Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis
Jin, R., Liu, B., Liu, X., Fan, Y., Peng, W., Huang, C., Marcus, A. I., Sica, G., Gilbert‐Ross, M., Liu, Y., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0567 · Cited by 23
The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis
Wang, W., Zhou, H., & Liu, L. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153136 · Cited by 24
Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study
Sun, Y. J., Xiaomeng, C., Xiaomin, D., Lin, J., Lv, P., Ma, L., Rongyi, C., Zongfei, J., Huiyong, C., & Jiang, L. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20930114 · Cited by 21
Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis
Reddy, S. V. B., Wanchu, A., Khullar, M., Govindrajan, S., & BAMBERY, P. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.11.013 · Cited by 21
Treatment of Juvenile Idiopathic Arthritis in the Biologic Age
Stoll, M. L., & Cron, R. Q. (2013) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2013.05.004 · Cited by 20
Leflunomide‐induced liver injury: Differences in characteristics and outcomes in Indian and US registries
Devarbhavi, H. C., Ghabril, M., Barnhart, H. X., Patil, M., Raj, S., Gu, J., Chalasani, N., & Bonkovsky, H. L. (2022) · Liver International · doi:10.1111/liv.15189 · Cited by 19
Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis
Inokuma, S., Sato, T., Sagawa, A., Matsuda, T., Takemura, T., Ohtsuka, T., Saeki, Y., Takeuchi, T., & Sawada, T. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0088-2 · Cited by 19
Determination of leflunomide in tablets by high performance liquid chromatography
Yeniceli, D., Doğrukol‐Ak, D., & Tunçel, M. (2005) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2005.06.030 · Cited by 17
Severe Cutaneous Adverse Drug Reaction to Leflunomide: A Report of Two Cases
Jian, X., Guo, G., Ruan, Y., Lin, D.-W., & Li, X. (2008) · Cutaneous and Ocular Toxicology · doi:10.1080/15569520701662866 · Cited by 15
The Significance of Heterocycles for Pharmaceuticals and Agrochemicals
Lamberth, C., & Dinges, J. (2012) · doi:10.1002/9783527664450.ch1 · Cited by 15
Natural History of Idiosyncratic Drug‐Induced Liver Injury and Prognostic Models
Devarbhavi, H. C., & Andrade, R. J. (2025) · Liver International · doi:10.1111/liv.70138 · Cited by 14
Immunosuppressive Therapy for Autoimmune Lung Diseases
Meyer, K. C., & Bierach, J. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.07.001 · Cited by 14
Severe aplastic anaemia following leflunomide therapy
Wusthof, M., Smirnova, A., Bacher, U., Kröger, N. M., Zander, A. R., Schuch, G., & Bokemeyer, C. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/kep406 · Cited by 13
Leflunomide Loaded Chitosan Nanoparticles for the Preparation of Aliphatic Polyester Based Skin Patches
Nanaki, S. G., Andrianidou, S., Barmpalexis, P., Christodoulou, E., & Bikiaris, D. Ν. (2021) · Polymers · doi:10.3390/polym13101539 · Cited by 13
Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study
Zeng, H., Liu, H., Liu, Z., Zhou, X., Lu, X., Yan, Z., Zhou, Y., Dai, L., Chen, Y., Yang, T., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2090176 · Cited by 12
Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum
Nakafero, G., Grainge, M. J., Card, T. R., Taal, M. W., Aithal, G. P., Zhang, W., Doherty, M., Fox, C. P., Mallen, C. D., & Abhishek, A. (2021) · Rheumatology · doi:10.1093/rheumatology/keab790 · Cited by 12
Convenient synthesis of highly functionalized isoxazoles including an amidine skeleton based on trichloroacetamidine, alkynes, and hydroxyimidoyl chloride
Nematpour, M. (2024) · Tetrahedron Letters · doi:10.1016/j.tetlet.2024.155443 · Cited by 11
Management of psoriatic arthritis
Sharma, A., & Dogra, S. (2010) · Indian Journal of Dermatology Venereology and Leprology · doi:10.4103/0378-6323.72457 · Cited by 11
LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma
Rule, G. S., Rockwood, A. L., & Johnson‐Davis, K. L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8823-5_8 · Cited by 10
Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease
Otsuka, T., Koyama, T., Ohtani, R., Niiro, H., Yoshizawa, S., Harada, M., & Inokuma, S. (2007) · Modern Rheumatology · doi:10.1007/s10165-007-0014-z · Cited by 10
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany
Schädlich, P. K., Zeidler, H. K., Zink, A., Gromnica‐Ihle, E., Schneider, M., Straub, C., Brecht, J. G., & Huppertz, E. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523040-00007 · Cited by 10
Bewertung von Wechselwirkungen und Dosierungsempfehlungen von synthetischen DMARDs – Evidenz- und konsensbasierte Empfehlungen auf Basis einer systematischen Literatursuche
Fiehn, C., Leipe, J., Weseloh, C., Bergner, R., & Krüger, K. (2023) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-022-01308-z · Cited by 9
Individualization of Leflunomide Dosing in Rheumatoid Arthritis Patients
Hopkins, A. M., O’Doherty, C., Foster, D. J. R., Upton, R. N., Proudman, S., & Wiese, M. D. (2014) · Personalized Medicine · doi:10.2217/pme.14.23 · Cited by 9
Leflunomide Sustained Skin Delivery Based on Sulfobetaine-Modified Chitosan Nanoparticles Embedded in Biodegradable Polyesters Films
Nanaki, S. G., Christodoulou, E., Bikiaris, N. D., Kapourani, A., Kontogiannopoulos, K. N., Vergkizi-Nikolakaki, S., & Barmpalexis, P. (2021) · Polymers · doi:10.3390/polym13060960 · Cited by 9
Determination of Leflunomide in Pharmaceutical Tablets by Flow‐Injection Analysis
Yeniceli, D., Doğrukol‐Ak, D., & Tunçel, M. (2005) · Journal of Liquid Chromatography & Related Technologies · doi:10.1081/jlc-200060448 · Cited by 9
Leflunomide in the treatment of rheumatoid arthritis
Kunkel, G. A., & Cannon, G. W. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.1.17 · Cited by 9
Leflunomide-induced acute liver failure: a case report
Yuyuan, L., & Xuqing, Z. (2010) · 中国人民解放军军医大学学报：英文版 · doi:10.1016/s1000-1948(10)60020-2 · Cited by 8
Novel therapies of lupus nephritis
Schieppati, A., & Remuzzi, G. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f4e54d · Cited by 8
Evolving strategies in the treatment of rheumatoid arthritis: a historical perspective
Domańska-Poboża, J., & Wisłowska, M. (2025) · Reumatologia/Rheumatology · doi:10.5114/reum/195012 · Cited by 7
Leflunomida: valoración del riesgo teratógeno en el primer trimestre de embarazo
Sorní, C. C., Romá‐Sánchez, E., Pellicer, A., & Andrés, J. L. P. (2005) · Farmacia Hospitalaria · doi:10.1016/s1130-6343(05)73675-8 · Cited by 7
Fabrication of Topical Pluronic Lecithin Organogel Containing Immunomodulatory Drug for Site-Specific Drug Delivery
Gohil, D., Shah, M., Shah, N. V., & Maheshwari, R. A. (2024) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.58.2.48 · Cited by 6
A convenient synthesis of 13C4‐Leflunomide and its primary metabolite 13C4‐A77 1726
Faragher, R. J., Motto, J. M., Kaminski, M. A., & Schwan, A. L. (2003) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.701 · Cited by 6
Regioselective Synthesis of 3, 5‐Disubstituted Isoxazole Catalyzed by Cu 2 O−ZnO Nanocomposite
Pardeshi, S. S., Labhane, P. K., Disale, S. T., More, D. H., & Sapkal, B. M. (2022) · ChemistrySelect · doi:10.1002/slct.202201818 · Cited by 5
Synthesis, structure and NMR study of fluorinated isoxazoles derived from hemi-curcuminoids
Nieto, C. I., Cornago, P., Cabildo, P., Sanz, D., Claramunt, R. M., Torralba, M. C., & Elguero, J. (2018) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2018.12.012 · Cited by 5
Wirtschaftlichkeit von Leflunomid bei sequentieller Basistherapie der rheumatoiden Arthritis in Deutschland
Sch�dlich, P. K., Zeidler, H. K., Zink, A., Gromnica‐Ihle, E., Schneider, M., Straub, C., Brecht, J. G., & Huppertz, E. (2004) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-004-0570-y · Cited by 5
Der Einsatz von Leflunomid bei der rheumatoiden Arthritis
Kr�ger, K., & Bolten, W. W. (2005) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-005-0694-8 · Cited by 5
Management of Rheumatoid Arthritis
Keating, G. M., & Jarvis, B. (2002) · Disease Management & Health Outcomes · doi:10.2165/00115677-200210010-00003 · Cited by 5
Self-citation
Management of Rheumatoid Arthritis
Carswell, C., Perry, C. M., & Ibbotson, T. (2003) · Disease Management & Health Outcomes · doi:10.2165/00115677-200311110-00006 · Cited by 5
Novel Isoxazole Functionalized Quinazolinone Derivatives and Their Anticancer Activity
Konda, S. K., Kanuri, A. K., Chennuri, B. K., Anjum, R., Trivedi, R., Patlola, M., Yamini, S., & Bhoomandla, S. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363224611128 · Cited by 4
Development and Validation of a Liquid Chromatographic Method for the Determination of Leflunomide: Application to in vitro Drug Metal Interactions
Sultana, N., Muhammad, S. A., Khan, M. M., & Nawaz, M. (2011) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201180336 · Cited by 4
Leflunomide as adjunct therapy for BK viremia management in pediatric kidney transplant recipients
Aldieri, A., Chandran, M. M., Matossian, D., Hariprasad, A., Magella, B., Lazear, D., Blanchette, E. D., Benz, E. G., & Bock, M. (2024) · Pediatric Transplantation · doi:10.1111/petr.14724 · Cited by 4
Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease
Otsuka, T., Koyama, T., Ohtani, R., Niiro, H., Yoshizawa, S., Harada, M., & Inokuma, S. (2008) · Modern Rheumatology · doi:10.3109/s10165-007-0014-z · Cited by 4
Repositioning antimalarial drugs as anticancer agents: focus on Tafenoquine
Barton, C. E., Blair, B., Godo, L., Gray, A., Heron-Goar, L., Hill, H. A., Long, A., Moore, H., Rickett, R., & Tomas, S. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114551 · Cited by 3

Authors: Prakash, A., & Jarvis, B.
Corresponding author: Prakash, Amitabh
Venue: Drugs
Publisher: Springer Science and Business Media LLC
Published: 1999
Volume: 58
Issue: 6
Pages: 1137-1164
ISSN: 0012-6667 (ISSN-L)
DOI: 10.2165/00003495-199958060-00010
OpenAlex: W2020790398
Cited by: 135
References: 67
Citations by year: 2026: 5 · 2025: 8 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 1 · 2014: 4 · 2013: 5 · 2012: 6
FWCI: 2.49
Type: journal article
Language: en
Open access: closed
Locations: Drugs (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Keywords: leflunomide, rheumatoid arthritis, immunomodulation, sulfasalazine, methotrexate, disease-modifying antirheumatic drugs, drug safety, adverse events, hepatotoxicity, drug interactions, pregnancy contraindication, pancytopenia, skin reactions, radiographic progression, functional disability
MeSH terms: Leflunomide, Adult, Animals, Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Rheumatoid, Female, Humans, Isoxazoles, Male, Pregnancy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Leflunomide: A Review of its Use in Active Rheumatoid Arthritis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks